Yupelri Not Superior to Spiriva in Phase 4 Trial
Theravance Biopharma's COPD treatment Yupelri was not superior to Boehringer Ingelheim's Spiriva Handihaler, according to results from a phase 4 study reported by Theravance.
Tag: Theravance
Yupelri Not Superior to Spiriva in Phase 4 Trial
Theravance Biopharma’s COPD treatment Yupelri was not superior to Boehringer Ingelheim’s Spiriva Handihaler, according to results from a phase 4 study reported by Theravance.
Read MoreIncruse/Breo Ellipta Combo Improved FEV1 in COPD Patients
Patients with COPD who received the anticholinergic Incruse Ellipta in addition to the ICS/LABA combo Breo Ellipta achieved an additional improvement in lung function compared to patients receiving FF/VI plus placebo, according to GlaxoSmithKline and Theravance.
Read MoreAnoro Ellipta Available In US For Treatment Of COPD
Anoro Ellipta (umeclidinium and vilanterol inhalation powder) — the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of COPD — is now available in US retail pharmacies.
Read MoreGSK Completes Enrollment for Landmark COPD-CVD Study
GlaxoSmithKline and Theravance have completed enrollment of 16,000 patients for SUMMIT, a study to determine the impact of GSK’s Breo Ellipta on all cause mortality amongst patients with moderate COPD and cardiovascular disease.
Read More
Breo Ellipta Gets FDA Approval for COPD
GlaxoSmithKline and Theravance Inc’s Breo Ellipta, an inhaled long-term, once-daily treatment for airflow obstruction in COPD patients, has received FDA approval.
Read More